Development of an artificial intelligence based Rapid On-Site Cytopathological Evaluationon (Rose) system for EUS-FNA of solid pancreatic lesions

Clinical study of EUS-FNA in rapid cytopathological artificial intelligence assisted assessment system for solid pancreatic lesions

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032664

Enrollment

Unknown

Registered

2020-05-05

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Gold Standard:Pathologist's examination of EUS-FNA specimens

Index test:EUS-FNA&#32

rapid&#32

cytopathological&#32

artificial&#32

intelligence&#32

assisted&#32

assessment&#32

system.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cell smear obtained from EUS-FNA in patients with solid pancreatic lesions 2. Qualified smear.

Exclusion criteria

Exclusion criteria: 1. Lack of important baseline data and failure to collect pictures with puncture smear; 2. The researchers think it is not suitable to be included in the system Model.

Design outcomes

Primary

Measure	Time frame
pancreatic puncture cell;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactLv Ying

The Affiliated Drum Tower Hospital of Nanjing University Medical School

13770755008@126.com+86 13770755008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026